Effect of an early therapeutic permutation on the tumoral control of patients receiving in first line a specific inhibitor of tyrosin kinase of EGFR [epidermal growth factor receptor] (erlotinib) or a taxan-based chemotherapy [paclitaxel] for the treatment of not resectable adenocarcinoma with bronchiolo-alveolar [bronchiolo-alveolar adenocarcinoma].

Trial Profile

Effect of an early therapeutic permutation on the tumoral control of patients receiving in first line a specific inhibitor of tyrosin kinase of EGFR [epidermal growth factor receptor] (erlotinib) or a taxan-based chemotherapy [paclitaxel] for the treatment of not resectable adenocarcinoma with bronchiolo-alveolar [bronchiolo-alveolar adenocarcinoma].

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2015

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
  • Indications Bronchiolo-alveolar adenocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2015 Primary endpoint (16-week Disease Control Rate) has been met according to the results published in the European Respiratory Journal.
    • 17 Sep 2015 Results published in the European Respiratory Journal.
    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top